Home World News Efficacy of Taletrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC World News Efficacy of Taletrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC By Ogkologos - April 18, 2025 967 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from an integrated analysis of the pivotal phase II regional TRUST-I and global TRUST-II studies Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR 5 questions the NHS Workforce Plan for England needs to answer June 27, 2023 Avapritinib Approved to Treat GIST with a Rare Gene Alteration February 6, 2020 FDA Grants Accelerated Approval to Umbralisib for Marginal Zone and Follicular... February 11, 2021 Julia Louis-Dreyfus Talks About The Side Effects of Chemotherapy May 3, 2019 Load more HOT NEWS Study Finds Possible New Treatment for Metastatic Breast Cancer That Has... Male Patients with Cancer at Higher Risk of Severe Disease Course... Bjorn Saven: “By supporting early career researchers to do their jobs... 27-Year-Old Diagnosed with Cancer at 20 Weeks Pregnant Gives Birth Amid...
